A streamlined workflow using Six Sigma's DMAIC methodology was developed to identify and mitigate visible particles in ...

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s ...

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market s | Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease ...

That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Pfizer not only beat expectations last quarter, but also boosted its guidance.

Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST ...

By now, you know that the COVID-19 vaccine is the best way to protect against severe COVID infections and reduce your chances ...